biote (BTMD) to Release Quarterly Earnings on Wednesday

biote (NASDAQ:BTMD) is projected to announce its Q3 2025 results after the market closes on Wednesday, November 5th. Analysts expect the company to announce earnings of $0.05 per share and revenue of $47.7580 million for the quarter. Individuals may visit the the company’s upcoming Q3 2025 earningresults page for the latest details on the call scheduled for Wednesday, November 5, 2025 at 5:00 PM ET.

biote (NASDAQ:BTMD) last issued its quarterly earnings results on Wednesday, August 6th. The company reported $0.10 earnings per share for the quarter, topping analysts’ consensus estimates of $0.06 by $0.04. biote had a negative return on equity of 21.00% and a net margin of 15.73%.The company had revenue of $48.86 million for the quarter, compared to analyst estimates of $49.52 million. On average, analysts expect biote to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

biote Stock Up 3.2%

Shares of biote stock opened at $2.87 on Monday. biote has a fifty-two week low of $2.65 and a fifty-two week high of $6.98. The firm has a market cap of $141.89 million, a PE ratio of 3.19 and a beta of 1.16. The business’s fifty day moving average is $3.11 and its two-hundred day moving average is $3.53.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in the company. Geode Capital Management LLC raised its position in shares of biote by 7.2% in the 2nd quarter. Geode Capital Management LLC now owns 616,697 shares of the company’s stock worth $2,480,000 after buying an additional 41,333 shares during the period. Bridgeway Capital Management LLC raised its position in biote by 142.1% in the second quarter. Bridgeway Capital Management LLC now owns 121,053 shares of the company’s stock valued at $487,000 after purchasing an additional 71,053 shares during the period. Marshall Wace LLP raised its position in biote by 26.6% in the second quarter. Marshall Wace LLP now owns 118,928 shares of the company’s stock valued at $478,000 after purchasing an additional 24,954 shares during the period. First Trust Advisors LP raised its position in biote by 5.3% in the second quarter. First Trust Advisors LP now owns 73,669 shares of the company’s stock valued at $296,000 after purchasing an additional 3,675 shares during the period. Finally, Man Group plc raised its position in biote by 419.1% in the second quarter. Man Group plc now owns 64,027 shares of the company’s stock valued at $257,000 after purchasing an additional 51,693 shares during the period. 21.68% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on the company. B. Riley lowered biote from a “buy” rating to a “neutral” rating and reduced their price target for the stock from $8.00 to $4.00 in a research note on Thursday, August 7th. Wall Street Zen lowered biote from a “buy” rating to a “hold” rating in a research report on Sunday. Finally, Weiss Ratings raised biote from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Friday, October 24th. One equities research analyst has rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $6.00.

biote Company Profile

biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification services; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and other administrative requirements; inventory management software to monitor pellet inventory; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support.